Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
Title:
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
Author:
Auliac, J. B. Fournier, C. Audigier Valette, C. Perol, M. Bizieux, A. Vinas, F. Decroisette Phan van Ho, C. Bota Ouchlif, S. Corre, R. Garff, G. Le Fournel, P. Baize, N. Lamy, R. Vergnenegre, A. Arpin, D. Marin, B. Chouaid, C. Gervais, R.